Merck will acquire ophthalmic-focused Inspire Pharmaceuticals for approximately $430 million in cash. The transaction was unanimously approved by the boards of both companies and Inspire’s board recommended that the company’s shareholders tender their shares pursuant to the tender offer. “Merck continues to build upon its long-term commitment to improving therapeutic options for the treatment of eye diseases,” said Beverly Lybrand, senior vice president and general manager, ...